Journal Article

Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation

Rudolf P. Wüthrich, Snjezana Cicvara, Patrice M. Ambühl and Ulrich Binswanger

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 15, issue 8, pages 1228-1231
Published in print August 2000 | ISSN: 0931-0509
Published online August 2000 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/15.8.1228
Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation

Show Summary Details

Preview

Background. In the first year after renal allograft transplantation, triple therapy immunosuppression with cyclosporin (CsA), prednisone (P), and mycophenolate mofetil (MMF) is superior to a triple therapy treatment that includes azathioprine (AZA) instead of MMF. Whether long‐term treatment with CsA‐P‐MMF is better than treatment with CsA‐P‐AZA is a matter of debate, as 3‐year graft survival is similar in MMF‐ and AZA‐treated patients. The purpose of the present study was to examine the short‐term effect of changing MMF to AZA in low‐risk renal allograft recipients 6 months after transplantation.

Method. This was a randomized, open‐label single‐centre study, recruiting 48 low risk renal allograft recipients on CsA‐P‐MMF therapy 6 months after transplantation, comparing the outcome with continued MMF treatment (2 g b.i.d.) (group A, n=22) or switching MMF to AZA (1 mg/kg) treatment (group B, n=26).

Results. The outcome after a 6‐months follow‐up of patients in group A and group B was similar. Treatment failure rates (defined as clinically diagnosed acute rejection episodes) were 4.5% in group A and 3.8% in group B. There were no patient deaths and no graft failures during the 6‐months observation period. Graft function was excellent and similar in both groups.

Conclusion. Replacing MMF with AZA 6 months after transplantation in low‐risk renal allograft recipients is safe and is not associated with altered graft function in the short term.

Keywords: CsA dosage; low‐risk kidney transplant recipients; mycophenolate mofetil to azathioprine conversion; prednisone; short‐term graft survival; six‐month trial

Journal Article.  1903 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.